GlassScriptPhysician profile
Amber R Rupiper
NPI 1679189971
$2,854.27
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $927 · 2023: $1,555 · 2024: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Travel and Lodging: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.94 |
| Travel and Lodging | $557.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,187.48 | 2023-2024 | Axonics |
| Teleflex LLC | $472.01 | 2022-2023 | Urolift |
| Sumitomo Pharma America, INC. | $216.35 | 2023-2024 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $127.71 | 2022 | |
| Astellas Pharma US INC | $121.45 | 2022 | |
| Genmab U.S., INC. | $119.32 | 2024 | Epkinly |
| Tolmar Pharmaceuticals, INC. | $105.50 | 2022 | |
| Janssen Biotech, INC. | $96.76 | 2022-2023 | Erleada |
| Dendreon Pharmaceuticals LLC | $75.44 | 2022-2023 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $71.29 | 2022-2024 | |
| Urovant Sciences INC | $68.20 | 2022 | |
| Merck Sharp & Dohme LLC | $37.70 | 2022-2024 | Keytruda |
| Abbvie INC. | $33.41 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $19.22 | 2022 | |
| Antares Pharma, INC. | $17.63 | 2024 | Xyosted |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.34 | 2022 | |
| Blue Earth Diagnostics | $14.58 | 2023 | |
| Progenics Pharmaceuticals, INC. | $14.56 | 2024 | |
| Myriad Genetic Laboratories, INC. | $13.78 | 2023 | Prolaris |
| Telix Pharmaceuticals | $13.07 | 2023 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Rupiper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.